Streamlined analytical strategy using resonance Rayleigh scattering signal amplification for nanoscale quantification of rasagiline in tablets with content assessment
Abstract Rasagiline (RSG), a prevalent drug for Parkinson’s disease, is classified as a monoamine oxidase inhibitor. These drugs operate by elevating dopamine levels in the brain, with the objective of alleviating symptoms related to the illness. This work utilized a sensitive and feasible experimen...
Saved in:
| Main Author: | Ahmed A. Abu-hassan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13065-025-01585-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neuroprotective role of acamprosate and rasagiline in epilepsy: In silico and in vivo study
by: Kumar Sandeep, et al.
Published: (2025-01-01) -
Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®)
by: M. R. Nodel
Published: (2011-09-01) -
Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
by: Schettino C, et al.
Published: (2016-09-01) -
Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
by: Yuyan Tan, et al.
Published: (2025-03-01) -
Dementia with Lewy bodies
by: O. S. Levin, et al.
Published: (2018-11-01)